|
|
||||||||
Opinion |
1
Department of Laboratory Medicine, Childrens Hospital,
2
Center for Cardiovascular Disease Prevention, The Leducq Center for Molecular and Genetic Epidemiology of Cardiovascular Disorders,
3
Divisions of Cardiovascular Disease and Preventive Medicine, Brigham and Womens Hospital, and, Departments of
4
Pathology and
5
Medicine, Harvard Medical School, Boston, MA 02115
a Address correspondence to this author at: Childrens Hospital, Department of Laboratory Medicine, 300 Longwood Ave., Boston, MA 02115. Fax 617-713-4347;
rifai@tch.harvard.edu.
| Introduction |
|---|
| References |
|---|
The following articles in journals at HighWire Press have cited this article:
![]() |
M. Guardiola, R. Ferre, J. Salazar, C. Alonso-Villaverde, B. Coll, S. Parra, L. Masana, and J. Ribalta Protease Inhibitor-Associated Dyslipidemia in HIV-Infected Patients Is Strongly Influenced by the APOA5-1131T->C Gene Variation Clin. Chem., October 1, 2006; 52(10): 1914 - 1919. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Jaffe, L. Babuin, and F. S. Apple Biomarkers in Acute Cardiac Disease: The Present and the Future J. Am. Coll. Cardiol., July 4, 2006; 48(1): 1 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Stefanska, G. Sypniewskay, and L. Senterkiewicz Inflammatory Markers and Cardiovascular Risk in Healthy Polish Women across the Menopausal Transition Clin. Chem., October 1, 2005; 51(10): 1893 - 1895. [Full Text] [PDF] |
||||
![]() |
G. L. Myers, N. Rifai, R. P. Tracy, W. L. Roberts, R. W. Alexander, L. M. Biasucci, J. D. Catravas, T. G. Cole, G. R. Cooper, B. V. Khan, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Laboratory Science Discussion Group Circulation, December 21, 2004; 110(25): e545 - e549. [Full Text] [PDF] |
||||
![]() |
R. Rej Clinical Chemistry through Clinical Chemistry: A Journal Timeline Clin. Chem., December 1, 2004; 50(12): 2415 - 2458. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Levinson, J. J. Miller, and R. J. Elin Poor Predictive Value of High-Sensitivity C-Reactive Protein Indicates Need for Reassessment Clin. Chem., October 1, 2004; 50(10): 1733 - 1735. [Full Text] [PDF] |
||||
![]() |
U. A. Ajani, E. S. Ford, and A. H. Mokdad Prevalence of High C-Reactive Protein in Persons with Serum Lipid Concentrations within Recommended Values Clin. Chem., September 1, 2004; 50(9): 1618 - 1622. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Ix, M. G. Shlipak, H. H. Liu, N. B. Schiller, and M. A. Whooley Association between Renal Insufficiency and Inducible Ischemia in Patients with Coronary Artery Disease: The Heart and Soul Study J. Am. Soc. Nephrol., December 1, 2003; 14(12): 3233 - 3238. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Khuseyinova, A. Imhof, G. Trischler, D. Rothenbacher, W. L. Hutchinson, M. B. Pepys, and W. Koenig Determination of C-Reactive Protein: Comparison of Three High-Sensitivity Immunoassays Clin. Chem., October 1, 2003; 49(10): 1691 - 1695. [Full Text] [PDF] |
||||
![]() |
T. B. Ledue and N. Rifai Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment Clin. Chem., August 1, 2003; 49(8): 1258 - 1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Ford, W. H. Giles, G. L. Myers, N. Rifai, P. M. Ridker, and D. M. Mannino C-reactive Protein Concentration Distribution among US Children and Young Adults: Findings from the National Health and Nutrition Examination Survey, 1999-2000 Clin. Chem., August 1, 2003; 49(8): 1353 - 1357. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.J. Malkin, P.J. Pugh, T.H. Jones, and K.S. Channer Testosterone for secondary prevention in men with ischaemic heart disease? QJM, July 1, 2003; 96(7): 521 - 529. [Full Text] [PDF] |
||||
![]() |
I. M. van der Meer, M. P. M. de Maat, A. J. Kiliaan, D. A. M. van der Kuip, A. Hofman, and J. C. M. Witteman The Value of C-Reactive Protein in Cardiovascular Risk Prediction: The Rotterdam Study Arch Intern Med, June 9, 2003; 163(11): 1323 - 1328. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Tsen, G.-Y. Kao, C.-L. Chang, F.-Y. Lai, C.-H. Huang, S. Ouyang, M.-H. Yu, C.-P. Wang, and Y-N. Chiou Evaluation and Validation of a Duck IgY Antibody-based Immunoassay for High-Sensitivity C-reactive Protein: Avian Antibody Application in Clinical Diagnostics Clin. Chem., May 1, 2003; 49(5): 810 - 813. [Full Text] [PDF] |
||||
![]() |
C.-H. Wang, S.-H. Li, R. D. Weisel, P. W.M. Fedak, A. S. Dumont, P. Szmitko, R.-K. Li, D. A.G. Mickle, and S. Verma C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle Circulation, April 8, 2003; 107(13): 1783 - 1790. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Kimberly, H. W. Vesper, S. P. Caudill, G. R. Cooper, N. Rifai, F. Dati, and G. L. Myers Standardization of Immunoassays for Measurement of High-Sensitivity C-reactive Protein. Phase I: Evaluation of Secondary Reference Materials Clin. Chem., April 1, 2003; 49(4): 611 - 616. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rifai and P. M. Ridker Population Distributions of C-reactive Protein in Apparently Healthy Men and Women in the United States: Implication for Clinical Interpretation Clin. Chem., April 1, 2003; 49(4): 666 - 669. [Full Text] [PDF] |
||||
![]() |
A. Imhof, M. Frohlich, H. Loewel, N. Helbecque, M. Woodward, P. Amouyel, G. D.O. Lowe, and W. Koenig Distributions of C-reactive Protein Measured by High-Sensitivity Assays in Apparently Healthy Men and Women from Different Populations in Europe Clin. Chem., April 1, 2003; 49(4): 669 - 672. [Full Text] [PDF] |
||||
![]() |
E. S. Ford, W. H. Giles, G. L. Myers, and D. M. Mannino Population Distribution of High-Sensitivity C-reactive Protein among US Men: Findings from National Health and Nutrition Examination Survey 1999-2000 Clin. Chem., April 1, 2003; 49(4): 686 - 690. [Full Text] [PDF] |
||||
![]() |
T. C. Vukovich, S. Mustafa, H. Rumpold, and O. Wagner Evaluation of a Turbidimetric Denka Seiken C-Reactive Protein Assay for Cardiovascular Risk Estimation and Conventional Inflammation Diagnosis Clin. Chem., March 1, 2003; 49(3): 511 - 512. [Full Text] [PDF] |
||||
![]() |
M. S. Beattie, M. G. Shlipak, H. Liu, W. S. Browner, N. B. Schiller, and M. A. Whooley C-Reactive Protein and Ischemia in Users and Nonusers of {beta}-Blockers and Statins: Data From the Heart and Soul Study Circulation, January 21, 2003; 107(2): 245 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sattar, C. G Perry, and J. R Petrie Type 2 diabetes as an inflammatory disorder The British Journal of Diabetes & Vascular Disease, January 1, 2003; 3(1): 36 - 41. [Abstract] [PDF] |
||||
![]() |
I. M. van der Meer, M. P.M. de Maat, A. E. Hak, A. J. Kiliaan, A. I. del Sol, D. A.M. van der Kuip, R. L.G. Nijhuis, A. Hofman, and J. C.M. Witteman C-Reactive Protein Predicts Progression of Atherosclerosis Measured at Various Sites in the Arterial Tree: The Rotterdam Study Stroke, December 1, 2002; 33(12): 2750 - 2755. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Middleton Effect of Analytical Error on the Assessment of Cardiac Risk by the High-Sensitivity C-Reactive Protein and Lipid Screening Model Clin. Chem., November 1, 2002; 48(11): 1955 - 1962. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Verma, C.-H. Wang, S.-H. Li, A. S. Dumont, P. W.M. Fedak, M. V. Badiwala, B. Dhillon, R. D. Weisel, R.-K. Li, D. A.G. Mickle, et al. A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis Circulation, August 20, 2002; 106(8): 913 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.J. de Winter, G.S. Heyde, K.T. Koch, J. Fischer, J.P. van Straalen, M. Bax, C.E. Schotborgh, K.J. Mulder, G.T. Sanders, J.J. Piek, et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty Eur. Heart J., June 2, 2002; 23(12): 960 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kushner and A. R. Sehgal Is High-Sensitivity C-Reactive Protein an Effective Screening Test for Cardiovascular Risk? Arch Intern Med, April 22, 2002; 162(8): 867 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Levinson High Density- and Beta-Lipoprotein Screening for Risk of Coronary Artery Disease in the Context of New Findings on Reverse Cholesterol Transport Ann. Clin. Lab. Sci., April 1, 2002; 32(2): 123 - 136. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sesmilo, W. P. Fairfield, L. Katznelson, K. Pulaski, P. U. Freda, V. Bonert, E. Dimaraki, S. Stavrou, M. L. Vance, D. Hayden, et al. Cardiovascular Risk Factors in Acromegaly before and after Normalization of Serum IGF-I Levels with the GH Antagonist Pegvisomant J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1692 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Levinson and R. J. Elin What Is C-Reactive Protein Telling Us About Coronary Artery Disease? Arch Intern Med, February 25, 2002; 162(4): 389 - 392. [Full Text] [PDF] |
||||
![]() |
P. Tarkkinen, T. Palenius, and T. Lovgren Ultrarapid, Ultrasensitive One-Step Kinetic Immunoassay for C-Reactive Protein (CRP) in Whole Blood Samples: Measurement of the Entire CRP Concentration Range with a Single Sample Dilution Clin. Chem., February 1, 2002; 48(2): 269 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Sesmilo, K. K. Miller, D. Hayden, and A. Klibanski Inflammatory Cardiovascular Risk Markers in Women with Hypopituitarism J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5774 - 5781. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hamwi, T. Vukovich, O. Wagner, H. Rumpold, R. Spies, M. Stich, and C. Langecker Evaluation of Turbidimetric High-Sensitivity C-Reactive Protein Assays for Cardiovascular Risk Estimation Clin. Chem., November 1, 2001; 47(11): 2044 - 2046. [Full Text] [PDF] |
||||
![]() |
R. P. Tracy Is Visceral Adiposity the "Enemy Within"? Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 881 - 883. [Full Text] [PDF] |
||||
![]() |
U.-H. Stenman Immunoassay Standardization: Is It Possible, Who Is Responsible, Who Is Capable? Clin. Chem., May 1, 2001; 47(5): 815 - 820. [Full Text] [PDF] |
||||
![]() |
N. Rifai and P. M. Ridker High-Sensitivity C-Reactive Protein: A Novel and Promising Marker of Coronary Heart Disease Clin. Chem., March 1, 2001; 47(3): 403 - 411. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Roberts, L. Moulton, T. C. Law, G. Farrow, M. Cooper-Anderson, J. Savory, and N. Rifai Evaluation of Nine Automated High-Sensitivity C-Reactive Protein Methods: Implications for Clinical and Epidemiological Applications. Part 2 Clin. Chem., March 1, 2001; 47(3): 418 - 425. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Meier-Ewert, P. M. Ridker, N. Rifai, N. Price, D. F. Dinges, and J. M. Mullington Absence of Diurnal Variation of C-Reactive Protein Concentrations in Healthy Human Subjects Clin. Chem., March 1, 2001; 47(3): 426 - 430. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Koenig C-Reactive Protein and Cardiovascular Risk: Has the Time Come for Screening the General Population? Clin. Chem., January 1, 2001; 47(1): 9 - 10. [Full Text] [PDF] |
||||
![]() |
S. Verma, S.-H. Li, M. V. Badiwala, R. D. Weisel, P. W.M. Fedak, R.-K. Li, B. Dhillon, and D. A.G. Mickle Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein Circulation, April 23, 2002; 105(16): 1890 - 1896. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |